Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial

Cella, David; Motzer, Robert J.; Suárez, Cristina; Blum, Steven I.; Ejzykowicz, Flavia; Hamilton, Melissa; Wallace, Joel; Şimşek, Burçin; Zhang, Joshua; Ivanescu, Cristina; Apolo, Andrea B.; Choueiri, Toni K.

doi:10.1016/s1470-2045(21)00693-8

Cited by 56 publications

(30 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nowadays, ICIs, especially those targeting PD-1 and PD-L1, have been approved for the treatment of various cancers. 23 – 25 , 405 Great success has been achieved in some solid tumors such as lung cancer and melanoma. 405 , 406 Nevertheless, ICIs are limited by the fact that only about one-third of patients respond to ICIs.…”

Section: New Advances In Targeting Autophagy Pyroptosis Ferroptosis A...mentioning

confidence: 99%

“…22 For the past few years, ICIs have made significant breakthroughs in the field of antitumor therapy. 23 – 25 Mechanically, ICIs inhibit cancer development by restoring the function of effector T cells. 17 , 19 Traditionally, it was believed that immunotherapy-activated CD8+ T cells induce tumor cell death mainly through the perforin-granzyme pathway and the Fas-Fas ligand (FASL) pathway.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy

Gao

Wang

Zhou

et al. 2022

Sig Transduct Target Ther

406

189

View full text Add to dashboard Cite

In recent years, immunotherapy represented by immune checkpoint inhibitors (ICIs) has led to unprecedented breakthroughs in cancer treatment. However, the fact that many tumors respond poorly or even not to ICIs, partly caused by the absence of tumor-infiltrating lymphocytes (TILs), significantly limits the application of ICIs. Converting these immune “cold” tumors into “hot” tumors that may respond to ICIs is an unsolved question in cancer immunotherapy. Since it is a general characteristic of cancers to resist apoptosis, induction of non-apoptotic regulated cell death (RCD) is emerging as a new cancer treatment strategy. Recently, several studies have revealed the interaction between non-apoptotic RCD and antitumor immunity. Specifically, autophagy, ferroptosis, pyroptosis, and necroptosis exhibit synergistic antitumor immune responses while possibly exerting inhibitory effects on antitumor immune responses. Thus, targeted therapies (inducers or inhibitors) against autophagy, ferroptosis, pyroptosis, and necroptosis in combination with immunotherapy may exert potent antitumor activity, even in tumors resistant to ICIs. This review summarizes the multilevel relationship between antitumor immunity and non-apoptotic RCD, including autophagy, ferroptosis, pyroptosis, and necroptosis, and the potential targeting application of non-apoptotic RCD to improve the efficacy of immunotherapy in malignancy.

show abstract

Section: New Advances In Targeting Autophagy Pyroptosis Ferroptosis A...mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy

Gao

Wang

Zhou

et al. 2022

Sig Transduct Target Ther

406

189

View full text Add to dashboard Cite

show abstract

“… 28 Compared with sunitinib, nivolumab plus cabozantinib was associated with improvements in FKSI-19 total score (median time to first deterioration 6.24 versus 3.48 months, HR = 0.70, 95% CI = 0.56–0.86, nominal p = 0.0007). 44 Discontinuation of any trial drug due to AEs occurred in 19.7% of patients receiving nivolumab plus cabozantinib and in 16.9% of patients receiving sunitinib, and grade ⩾3 AEs were reported in 60.6% and 50.9% of patients, respectively. One death attributed to treatment was reported in the combination arm (0.3% of patients) and two occurred in the sunitinib group (0.6%).…”

Section: Resultsmentioning

confidence: 98%

Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review

Lalani

Heng

Basappa³

et al. 2022

Ther Adv Med Oncol

View full text Add to dashboard Cite

Background: Renal cell carcinoma (RCC) is a common malignancy with approximately 30% of cases diagnosed at the advanced or metastatic stage. While single-agent vascular endothelial growth factor-targeted therapy has been a mainstay of treatment, data from multiple phase III trials assessing first-line immune checkpoint inhibitor (ICI) combinations have demonstrated a significant survival benefit. Methods: A systematic search of the published and presented literature was performed to identify phase III trials assessing ICI combination regimens in RCC using search terms ‘immune checkpoint inhibitors’ AND ‘renal cell carcinoma,’ AND ‘advanced’. Results: Six phase III trials showed significant benefits for ICI combinations compared with sunitinib. Nivolumab plus ipilimumab significantly improved overall survival [OS; median, 47.0 versus 26.6 months, hazard ratio (HR) = 0.68, 95% confidence interval (CI) = 0.58–0.81, p < 0.0001) and progression-free survival (PFS; median 11.6 versus 8.3 months, HR = 0.73, 95% CI = 0.61–0.87, p = 0.0004) in International Metastatic renal cell carcinoma Database Consortium intermediate and poor-risk patients. OS was also significantly improved for ICI plus tyrosine kinase inhibitor combinations regardless of risk, including pembrolizumab plus either axitinib (HR = 0.73, 95% CI = 0.60–0.88, p < 0.001) or lenvatinib (HR = 0.66, 95% CI = 0.49–0.88, p = 0.005) and nivolumab plus cabozantinib (HR = 0.66, 95% CI = 0.50–0.87, p = 0.003). No new safety signals were identified. Conclusions: Phase III first-line trials of ICI combinations showed survival benefits compared with a control arm of sunitinib. Global access to these combinations should be made available to patients with advanced RCC.

show abstract

“…Eine aktuelle, umfassende Analyse dieser Daten gibt nun Einblick in die Patient*innenperspektive [9]. Die Einschätzungen der Patient*innen zur Lebensqualität wurden jeweils am ersten Tag jeder Therapiewoche vor Behandlungsbeginn mittels der Fragebögen FKSI-19 (Functional Assessment of Cancer Therapy-Kidney Symptom Index) und EQ-5D-3L (European Quality of Life 5-Dimensions 3-Level Version) erfasst.…”

Section: Systematische Erfassung Des Prounclassified

“…Anhand einer Mixed-Model-Analyse für wiederholte Untersuchungen (mixed model for repeated measures; MMRM) wurden Score-Veränderungen im Längsschnitt abgebildet. Zu den untersuchten Punkten zählten unter anderem der Behandlungsarm, der Zeitpunkt, der IMDC-Prognose-Score (International Metastatic Renal-Cell Carcinoma Database Consortium Score), der PD-L1 (Programmed Cell Death Ligand 1)-Status und die Region [9].…”

Section: Systematische Erfassung Des Prounclassified

PharmaNews

2022

Oncol Res Treat

View full text Add to dashboard Cite

Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial

Cited by 56 publications

References 24 publications

Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy

Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy

Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review

PharmaNews

Contact Info

Product

Resources

About